Hepatobiliary disorder

This study looks at whether a second, inactivated hepatitis A vaccine can safely boost protection in healthy Thai children and teens who did not develop enough antibodies after a single dose of a live-attenuated hepatitis A vaccine. About 36 participants who took part in an earli…

This early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works again…

This study tests a new drug called elafibranor in people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants either did not get enough help from or could not take the standard medicine. The goal is to see if elafi…

This study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…

This phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…

This phase III trial tests whether proton radiation therapy works better than standard photon (X-ray) radiation for people with liver cancer that cannot be removed by surgery or has come back. The study involves 115 participants and compares overall survival and side effects. Pro…

This study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug im…

This Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…

This study tests a drug called odevixibat in 180 children with biliary atresia, a rare liver disease. The goal is to see if the drug helps children stay alive without needing a liver transplant over the long term. Children who completed a previous study can join this open-label e…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests whether elafibranor, a daily pill, can normalize alkaline phosphatase (ALP) levels in adults with primary biliary cholangitis (PBC) who did not respond well to or cannot take standard treatment. About 69 participants will receive either elafibranor or a placebo f…

This study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejecti…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This study tests a new drug called HM15211 in 215 adults with NASH, a liver condition that can lead to scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can reduce liver inflammation and scarring without making it worse…

This study tests an experimental drug, GSK4532990, in 284 adults with nonalcoholic steatohepatitis (NASH) and advanced liver scarring. The goal is to see if the drug can improve liver fibrosis and inflammation compared to a placebo over 52 weeks. Participants must have a liver bi…

This Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is re…

This study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…

This study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…

This study tests two doses of K-808 (Pemafibrate) in 46 adults with primary biliary cholangitis (PBC) who haven't responded well to standard treatments. The main goal is to see if the drug lowers alkaline phosphatase (ALP) levels, a key marker of liver damage, after 12 weeks. Par…

This phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…

This phase 2 trial tests two experimental drugs, Elebsiran and Tobevibart, in 95 adults with chronic hepatitis D, a serious liver infection. Participants receive the drugs as injections along with a standard oral antiviral. The goal is to see if the combination can lower virus le…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it f…

This phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…

This study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…

This phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…

This study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…

This study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This phase II trial tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) works better than chemotherapy alone for advanced biliary tract or gallbladder cancer. The study enrolls 57 adults who have not had prior treatment. Researc…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) before and after a standard tumor-burning procedure (radiofrequency ablation) can prevent small liver cancers from returning. About 202 adults with early-stage liver cancer will be randomly ass…

This study tests whether a personalized addiction monitoring program helps liver transplant patients avoid serious alcohol relapse one year after surgery. Researchers will follow 64 adults who are being evaluated for a liver transplant at a French hospital. The program includes m…

This early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…

This study compares a combination diabetes drug (iGlarLixi) against insulin alone to see which better reduces liver fat in people with type 2 diabetes and a common fatty liver condition called MASLD. About 36 participants will take one of the two treatments for 12 weeks, and doct…

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…

This long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…

This phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …

This study looks at whether giving chemotherapy both before and after surgery helps people with stage II-III gallbladder cancer live longer compared to the usual approach of only giving chemo after surgery. About 186 participants will be randomly assigned to one of two groups. Th…

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests a drug called tenofovir alafenamide (TAF) in 150 children and teens with chronic hepatitis B. Half receive TAF and half receive a placebo for 24 weeks. Researchers are checking how safe the drug is, how the body processes it, and whether it lowers virus levels. T…

This study tests whether combining the drug regorafenib with a targeted radiation treatment (Y-90 radioembolization) can control liver cancer that cannot be removed by surgery. About 30 adults with this type of liver cancer will receive the combination therapy. The main goals are…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …

This trial investigates whether adding secretin—a hormone that helps produce bicarbonate—during machine perfusion of donor livers can restore the protective 'bicarbonate umbrella' in bile ducts. Researchers will treat up to 20 donor livers with secretin while they are kept on a m…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study follows 200 people with nonalcoholic fatty liver disease (NAFLD) who receive an intragastric balloon—a device placed in the stomach to help with weight loss. Researchers will track changes in weight, liver enzymes, blood sugar, and liver stiffness for at least one year…

This study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …

This early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …

This study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…

This study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is …

This early-phase trial tests whether giving the immunotherapy drugs nivolumab (Opdivo) with or without relatlimab before and after surgery is safe and feasible for people with liver cancer that can be removed. About 31 participants will receive the drugs before surgery, then cont…

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…

This study compares a new treatment called TheraSphere (tiny radioactive beads) to standard chemoembolization for people with liver cancer that cannot be removed by surgery. About 92 Chinese adults with early-to-mid stage liver cancer will be randomly assigned to one of the two t…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a standard two-drug combination (lenvatinib and a PD-1 inhibitor) helps people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will receive either the …

This phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and contr…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also look at blood tests to see if…

This study tests whether a special formula diet can help people with non-alcoholic fatty liver disease (NASH) lose weight and improve liver health. About 20 overweight adults will follow the diet to see if it reduces liver fat and scarring. The goal is to find a safe, effective w…

This study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …

This study tests whether technology and caregiver support can help liver transplant recipients take their medications correctly. Researchers will enroll 360 adults who received a liver transplant within the past 3 months. Participants will use a system called Way to Health, which…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…

This early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…

This study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This phase 3 study tests whether a daily pill called resmetirom can prevent serious liver events like liver failure, need for transplant, or bleeding in people with NASH cirrhosis. About 845 adults with well-compensated cirrhosis will receive either the drug or a placebo. The goa…

This Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…

This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease…

This phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…

This study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This study tests whether a moderately low-carb diet can reduce liver fat and improve how the body uses insulin in teenagers with non-alcoholic fatty liver disease (NAFLD) and obesity. About 80 teens aged 10-17 will follow either a carb-restricted or a low-fat diet for 6 months, w…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This phase 2 trial tests whether simvastatin, a widely used cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers change. The goal is to …

This study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This study tests a blood-filtering treatment called DPMAS for people with severe liver failure. The goal is to see if it can lower the risk of death or worsening disease within weeks. About 1300 adults with chronic liver disease and high bilirubin levels are taking part. Research…

This study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…

This study tested whether a 12-week online Mediterranean diet program could reduce liver fat in people with a type of fatty liver disease (MASLD). 78 adults followed either the diet program or received standard advice. The goal was to see if the diet could improve liver health an…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancer live longer. About 810 participants received either durvalumab or a placebo alongside chemo. The study m…

This study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …

This trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to…

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This study tested a combination of two chemotherapy drugs, irinotecan and carboplatin, as the first treatment for children and adults newly diagnosed with intermediate- or high-risk rhabdomyosarcoma, a type of muscle cancer. The goal was to see if this drug pair could shrink tumo…

This phase 2 trial tests whether a powerful mix of liver-directed chemotherapy, a targeted drug (lenvatinib), and an immunotherapy (cadonilimab) can shrink liver cancers that were too large or widespread to remove. The goal is to convert these inoperable tumors into ones that can…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This study is a registry that collects information from up to 5,000 people who received a liver transplant after the donated liver was treated with the VitaSmart HOPE system. The device keeps the liver cool and oxygenated before transplant. The goal is to see how well the device …

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…

This study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…

This study looks at a new way to do liver transplants for people with severe portal hypertension. Instead of using a full-sized liver, doctors will use a smaller piece (small-for-size graft) in an auxiliary transplant, leaving part of the original liver in place. The goal is to s…

This study tests a supplement made from nopal, cacao, and cricket in 60 adults with fatty liver disease (MASLD). Participants take the supplement or a placebo daily for 3 months, along with dietary guidance. The goal is to see if the supplement reduces liver fat, improves health …

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…

This study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…

This study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…

This study gives continued access to a device that preserves donated livers before transplant. It includes 120 adults on the transplant waiting list. The goal is to collect safety data and check for early signs of liver problems after surgery.

This study tests whether a new weekly injection called IBI362 works better than the existing drug semaglutide for weight loss and reducing liver fat in overweight or obese Chinese adults with metabolic dysfunction-associated fatty liver disease (MAFLD). About 479 participants wil…

This phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and helps control the disease. About 102 adults who completed a previous PBC study will take the drug and be mon…

This study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …

This study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be …

This study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…

This study was designed to see if a new concentrated fibrinogen product works better than the standard one for controlling bleeding in liver transplant patients. It planned to enroll adults having a cadaveric liver transplant who were at risk for low fibrinogen levels. However, t…

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…

This Phase 2 trial tests an experimental drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can clear the hepatitis B surface antigen and lower the virus to undetectable levels, potentially leading to a func…

This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…

This study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…

This phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …

This early-phase trial tests whether infusing specially grown donor-specific regulatory T cells (Tregs) can allow liver transplant recipients to safely reduce or stop their anti-rejection medications. Nine participants will receive a single dose of these cells and be monitored fo…

This study is testing the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who have taken seladelpar before will receive either 5 mg or 10 mg daily for several years. Researchers will monitor …

This phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…

This study tests an injection called AHB-137 in 20 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug can lower or eliminate hepatitis B surface antigen (HBsAg) and viral DNA, potentially leading to a functional cure. Parti…

This early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…

This phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. Th…

This study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…

This study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial inv…

This study tests whether Ganoderma lucidum (a type of mushroom) can improve antioxidant levels and liver health in people with Metabolic Associated Fatty Liver Disease (MAFLD). Forty adults aged 35-49 with early-stage fatty liver will take the mushroom supplement. Researchers wil…

This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Rese…

This study tests whether beta-blockers, a type of blood pressure medicine, can reduce the risk of bleeding from small varices in people with cirrhosis and portal hypertension. About 763 adults with small varices will receive either beta-blockers or a placebo for up to 3 years. Th…

This study tests whether a smartphone app can help Chinese adults with non-alcoholic fatty liver disease (NAFLD) lose weight over 12 months. Weight loss is currently the only proven way to reverse liver fat and prevent serious complications. The trial will enroll 260 participants…

This early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…

This study looks at whether SGLT2 inhibitors, a type of diabetes medication, can help control ascites (fluid buildup in the belly) in people with liver cirrhosis and type 2 diabetes. Researchers will compare 40 patients who add the drug to their usual treatment against those who …

This early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …

This Phase 3 study tests whether efruxifermin, given as a weekly shot, is safe and can improve liver health in 700 adults with NASH/MASH (a type of fatty liver disease). Participants receive either the drug or a placebo. The study tracks side effects and measures changes in liver…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…

This study tests a combination of the drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) in 16 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay the cancer from getting worse. About 342 adults with liver cancer who are not cand…

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 wee…

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…

This study looks at whether a non-surgical stomach-reducing procedure called endoscopic sleeve gastroplasty (ESG) can help obese people with nonalcoholic fatty liver disease lose weight and improve liver health. Researchers will measure changes in liver fat and stiffness, as well…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study looks at whether eating three soybean-oil-based foods each day for 16 weeks can lower fat buildup in the liver and belly fat in people with nonalcoholic fatty liver disease. Participants keep their usual weight during the trial. The goal is to see if changing the type …

This study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy a…

This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This study tests whether a Mediterranean diet combined with intermittent fasting can reduce liver scarring (fibrosis) better than the weight-loss medication naltrexone/bupropion. About 70 adults with overweight or obesity and heart or metabolic risks (like type 2 diabetes or high…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…

This early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…

This study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…

This early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…

This trial tests whether a smartphone app and remote diet/exercise coaching can help people with non-alcoholic fatty liver disease lose weight and reduce liver fat. 120 participants will either get standard lifestyle advice or use the app with daily meal tracking, weekly recipe a…

This study tests whether a monitored ketogenic diet is safe and effective for weight loss in 40 obese adults with compensated NASH cirrhosis. Participants are randomly assigned to either a ketogenic diet or standard dietary advice for 16 weeks. The main goals are to check for liv…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study looks at whether ursodeoxycholic acid, a bile acid pill, can reduce the size of gallbladder polyps in 36 patients. The goal is to see if the treatment can help patients avoid surgery or frequent follow-up scans. Participants take the pill daily for at least six months,…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring from MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body processes it. Researchers will also check if it can reduce liver stiffnes…

This phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…

This study tests a behavioral program called contingency management for people who have had a liver transplant due to alcohol-related liver disease and have started drinking again. Participants get rewards like gift cards for staying alcohol-free, measured by urine and blood test…

This study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and …

This study tests whether semaglutide (Wegovy), a once-weekly injection, can preserve the pancreas's ability to produce insulin and reduce liver fat in 60 obese youth with prediabetes or early type 2 diabetes and fatty liver disease. Participants receive either semaglutide or a pl…

This early-phase trial tests whether injecting special liver-like cells into the abdominal muscle can help prevent or treat Small-for-Size syndrome, a serious complication that can occur after partial liver surgery. The study involves 12 patients and focuses mainly on safety, che…

This early-phase study tests whether taking prebiotic fiber and probiotics can improve fatty liver disease in people with HIV. Researchers believe changes in gut bacteria may contribute to liver problems. The trial involves 63 participants and measures liver fat and gut health ma…

This study tests a new oil called T-ACE Oil, mixed with a chemotherapy drug, for people with liver cancer that cannot be removed by surgery. The oil is injected directly into the liver's blood vessels to block them and deliver chemo to the tumor. The trial aims to see if it is sa…

This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.

This study tests a new, less invasive way to remove gallstones using a tube placed through the stomach or intestine into the gallbladder. The goal is to clear the stones while keeping the gallbladder intact, potentially avoiding the risks of traditional surgery. Sixty adults with…

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This study tests whether ambrisentan, a drug approved for lung blood pressure, can help patients with hepatorenal syndrome—a serious kidney problem that can occur in advanced liver cirrhosis. About 54 hospitalized adults will receive either ambrisentan or the standard drug terlip…

This study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…

This Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the …

This early-phase trial tests whether a gene-edited pig liver, used outside the body like a dialysis machine, can temporarily support liver function in one person with severe liver failure. The goal is to keep the patient stable until a human liver transplant becomes available. Pa…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…

This study tests a program where trained peers use motivational interviewing to encourage people who use drugs to check their drugs for dangerous substances and adopt safer use behaviors. The goal is to reduce fatal and non-fatal overdoses, as well as HIV and hepatitis C infectio…

This study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This study compares two diabetes medications, semaglutide and sitagliptin, in 58 adults who have had a liver transplant and have poorly controlled diabetes. The goal is to see which drug better lowers blood sugar and body weight. Participants will take the study drug daily for th…

This study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…

This phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study looks at whether giving pantoprazole (a stomach acid reducer) after endoscopic treatment for enlarged veins in the esophagus or stomach can lower the chance of bleeding in people with liver cirrhosis. About 208 adults will take part. The goal is to see if short-term us…

This study looks at 100 people with gallstones that have moved into the bile duct. One group gets the usual two-step treatment: first a scope to remove the bile duct stone, then surgery to remove the gallbladder. The other group gets a single surgery where the gallbladder is remo…

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…

This study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study looks at whether a 26-week behavioral weight loss program called 'Paso a Paso' is practical for Mexican and Central American adults with fatty liver disease and overweight. Researchers will track attendance, weight loss, liver stiffness, and diet changes in 50 particip…

This early-phase trial tests a single injection of HCL001 cells in 39 people with decompensated cirrhosis, a severe form of liver disease. The study aims to check safety and see if the treatment can improve liver function. Participants receive one of three dose levels, and resear…

This Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …

This study tests whether a drug called Angiotensin II can help control blood pressure during liver transplant surgery, reducing the need for other strong blood pressure medicines. It involves 50 adults with severe liver disease who are receiving a liver from a deceased donor. The…

This study tests a smartphone app that uses artificial intelligence to help liver transplant recipients manage their health after surgery. Researchers will track whether the app improves patients' confidence, daily self-care, and quality of life, and reduces emergency visits or i…

This study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…

This pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…

This early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive …

This phase 3 trial tests whether a herbal extract called Picroliv can help people with non-alcoholic fatty liver disease (NAFLD). 170 adults with mild to moderate NAFLD will take either Picroliv or a placebo twice daily for 24 weeks, alongside standard lifestyle advice. The main …

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This phase 2 study tests a new drug called CS0159 in 75 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants receive either CS0159 or a placebo for 12 weeks, followed by 40 weeks of open-label treatment. The goal is to see if CS0159 is safe and can…

This study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This Phase 2 trial tests an experimental drug called CS0159 in 50 people with primary sclerosing cholangitis (PSC), a rare liver disease. The study has a 12-week placebo-controlled phase followed by a 40-week open-label period to check safety and how well the drug works. Research…

This phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 inject…

This study looks at whether a very low-calorie diet (800-960 calories per day) can reduce fat and scarring in the liver for people with obesity and non-alcoholic fatty liver disease (NAFLD). Twenty participants will follow either the low-calorie diet or a standard lower-calorie d…

This program provides futibatinib (TAS-120) to adults with advanced bile duct cancer that has a specific FGFR2 gene change and who have no other treatment options. Participants take one 20 mg pill daily. The goal is to give access to this drug while it is being studied further.

This phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…

This global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …

This study is testing a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The microspheres are tiny glass beads containing radioactive yttrium-90, which are injected into the liver's blood vessels to deliver radiation directly to …

This early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …

This early-phase trial tests a new experimental treatment called CATCH T cells in up to 12 adults with certain solid tumors (like liver cancer or Wilms tumor) that have returned or not responded to standard care. The cells are the patient's own T cells, genetically modified in th…

This phase 2 trial is testing the drugs atezolizumab and bevacizumab in 36 people with inoperable liver cancer or non-small cell lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control and to study changes in tumors and blood before an…

This phase 2 trial is testing the drug pembrolizumab in 30 people with advanced liver cancer linked to hepatitis B. Participants receive pembrolizumab every 3 weeks, and researchers will check how the tumors respond and how the immune system changes. The goal is to see if this im…

This phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.

This study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…

This study tests a lifestyle program called Healthy Liver/Hígado Sano for Hispanic patients with metabolic-dysfunction associated steatotic liver disease (MASLD), also known as fatty liver disease. The program includes education sessions and family support to help participants lo…

This study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can reduce liver fat, inflammation, and scarri…

This study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting. The goal is to see if the drug can lower the virus level and improve liver h…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…

This early-stage trial is testing whether stem cells from donated umbilical cords can help people with liver cirrhosis caused by hepatitis B. The study will give 12 patients an intravenous infusion of these stem cells and monitor their liver function, Child-Pugh score, and MELD s…

This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This early-phase study tests a portable device that sends gentle electric fields to the liver, combined with chemotherapy and a targeted drug (bevacizumab), in people whose cancer has spread to the liver and stopped responding to standard treatments. The main goal is to find the …

This study tests whether a personalized, behavior-based program can help people with early liver disease (fatty liver or scarring) manage their condition better than standard care. About 49 adults with risk factors like obesity or diabetes are taking part. The goal is to see if t…

This study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patient…

This phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This was a planned Phase 1 study to test NP-101, a drug made from black seed, in people with liver cancer that cannot be removed by surgery. Participants would have taken NP-101 daily for 28 days before receiving standard Y-90 radiation treatment. The goal was to find the safest …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study tests whether using two contrast dyes during MRI can better tell apart benign and malignant liver lesions. About 100 patients with known or suspected liver growths will receive both gadoxetate disodium and gadobutrol before imaging. The goal is to see if the combinatio…

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study tests whether an AI system can help doctors identify patients with fatty liver disease who need specialist care. About 8,000 adults getting routine CT scans will have their images analyzed by AI to flag those at risk. The goal is to see if AI can improve detection and …

This study tests a computer system that automatically finds fatty liver disease on emergency room scans and alerts doctors to tell patients and arrange follow-up care. About 4,700 adults with fatty liver seen on an ER scan will take part. The goal is to improve how often this hid…

This study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…

This study follows 300 children aged 9 to 14 with obesity to see if ultrasound and MRI can detect early signs of liver disease. Researchers will compare imaging markers like liver fat and stiffness with standard tests. The goal is to improve diagnosis and monitoring without invas…

This study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…

This study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…

This study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This study aims to see if a special MRI scan can accurately detect liver scarring (fibrosis) in people with a liver condition called MASH. Researchers will compare the MRI results with standard tests like ultrasound and blood work in 50 adults. If successful, this could offer a n…

This study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion v…

This study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …

This study checks if a quick ultrasound device called Velacur can accurately detect fatty liver disease (MASLD) in children aged 2 to 20. About 200 kids with suspected liver issues will get the ultrasound, and results will be compared to MRI or liver biopsy. The goal is to find a…

This study looks at whether two blood markers, PLIN2 and RAB14, can accurately diagnose NASH (a serious liver disease) and advanced scarring, without needing a liver biopsy. Researchers will test these markers in 828 adults with NASH, type 2 diabetes, or obesity. If successful, t…

This study tests a new MRI technique that measures liver fat, fibrosis, and inflammation in a single 14-second breath-hold, without needles or contrast dye. Researchers will scan 120 people with fatty liver disease (60 with simple steatosis and 60 with NASH) and compare results t…

This study was designed to test a new thermo-acoustic imaging device that may help diagnose fatty liver disease without invasive procedures. It would have compared the device's accuracy to standard MRI scans in adults aged 18-70 with known or suspected fatty liver. However, the s…

This study tests whether a low-radiation CT scan, enhanced with artificial intelligence software, can detect liver tumors as accurately as a standard CT scan. About 146 adults with colorectal cancer and known liver metastases will receive both scans. The goal is to see if the low…

This phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce moth…

This study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …

This study tests whether giving a drug called angiotensin 2 during liver transplant surgery can prevent acute kidney injury, a common and serious complication. About 30 adults with end-stage liver disease will be randomly assigned to receive either the drug plus standard care or …

This study tests whether removing the fallopian tubes during planned gallbladder removal surgery is safe for women aged 45 and older. The goal is to see if this extra step can help prevent ovarian cancer without causing more complications. About 300 women will take part, with hal…

This study looks at the long-term safety and effectiveness of odevixibat in 70 people with Alagille syndrome, a rare genetic condition that affects the liver and other organs. The drug aims to reduce severe itching and improve bile flow. Participants who completed a prior 24-week…

This study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…

This study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…

This early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or in…

This study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…

This study looks at whether exercising once a week or three times a week is better at reducing liver fat in adults who are centrally obese and have non-alcoholic fatty liver disease (NAFLD). Three hundred Chinese adults aged 18-69 will be assigned to either a once-weekly or thric…

This early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…

This study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study tests whether giving methadone and ketamine during a deceased donor liver transplant can lower pain and confusion after surgery. About 50 adults will receive either the drug combo or standard care. Researchers will track pain scores, opioid use, and recovery time.

This study looks at two ways to give a pain-relieving injection (TAP block) to people having their gallbladder removed by keyhole surgery. One group gets the injection only on the right side, the other gets it on both sides. Researchers will track how long it takes before patient…

This Phase 3 trial tests whether maralixibat, an oral solution, can safely reduce severe itching (pruritus) in children and adults with rare cholestatic liver diseases. The study enrolls 90 participants aged 6 months and older who have not responded to other treatments. Over 20 w…

This study tests whether warming the saline used during laparoscopic gallbladder surgery or adding a numbing medicine can lessen shoulder pain afterward. About 216 adults having planned gallbladder removal will take part. The goal is to find a simple way to improve comfort and sp…

This study tests whether a mobile app-based nutritional program can help people living with HIV and fatty liver disease lose at least 5% of their body weight in 6 months. Participants are randomly assigned to use the app or receive standard lifestyle advice. The goal is to find a…

This early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…

This phase III trial compares two pain relief methods for patients undergoing open liver surgery for cancer: thoracic epidural analgesia and a four-quadrant TAP block. The study aims to see which method leads to a shorter hospital stay and better pain control. About 101 participa…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether teenagers and young adults with Polycystic Ovary Syndrome (PCOS) have more fat in their liver than those without PCOS. Researchers will use advanced imaging and tests to measure liver fat, insulin resistance, and cholesterol problems in 80 participants…

This study looks at a rare liver disease called PFIC, which causes severe itching and liver damage. Researchers compare patients who took the drug odevixibat to those who did not, using data from past studies and a patient registry. The goal is to see if odevixibat helps avoid li…

This study collects tumor tissue from 480 people with advanced biliary tract cancer in Taiwan to analyze their genetic makeup. The goal is to create a detailed map of genetic changes in this cancer, which could help identify potential targeted therapies. Participants are already …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…

This early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The go…

This study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This observational study looks at the financial and social challenges faced by informal caregivers of people with cirrhosis. Researchers will measure out-of-pocket costs, lost work time, and financial distress using surveys. The goal is to understand how these burdens affect care…

This study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …

This study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…

This study was designed to look at how tiny energy-producing parts of cells (mitochondria) in the liver might be linked to fatty liver disease in people with obesity who were scheduled for weight-loss surgery. Researchers planned to take small liver samples during surgery to stud…

This study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…

This study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…

This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …

This study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This pilot study compares two approaches to giving fluids during liver transplant surgery: a restrictive strategy that removes some blood early and returns it later, versus a liberal strategy that keeps blood flow high. The goal is to see if a larger study is possible by checking…

This study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…

This study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…

This study reviews medical records of 126 adults treated for liver or bile duct diseases (both non-cancerous and cancerous) since 2005. The goal is to see how well different treatments work and to find ways to improve survival, control symptoms, and lower risks. No new treatments…

This study at Stanford University is testing whether wearable devices like smartwatches can help measure fatigue, sleep, and daily activity in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare data from the wearables with patient que…

This study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …

This study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study follows up to 90 children and young adults with mitochondrial liver diseases to learn how these conditions progress over time. Researchers will collect medical data and samples to better understand the diseases and find markers that predict outcomes. The goal is to imp…

This study looks at how the liver burns fat and makes sugar in people with NASH (a serious liver disease linked to obesity) who are planning to have weight-loss surgery. Researchers will use special scans to measure liver function before and after surgery in 30 adults. The goal i…

This study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to…

This study followed children and young adults with genetic liver diseases that cause bile buildup. The goal was to track how these diseases progress over time, including the need for liver transplants or other complications. No treatments were tested; the aim was simply to learn …

This study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …

This study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study looks at how much oxalate the body naturally makes in people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a type of fatty liver. Researchers will collect urine samples from 28 adults after they eat a special low-oxalate diet. The goal is to be…

This study looks at how often people with type 1 diabetes have fatty liver disease and serious liver scarring. Researchers used a special ultrasound and blood tests to check 533 adults. The goal is to find high-risk patients who need a liver specialist.

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…

This study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help …

This study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…

This study looks at whether an electronic cognitive test called BrainCheck can effectively screen mental function in 100 patients scheduled for liver surgery. Researchers will compare how well patients complete the digital test versus a traditional pen-and-paper assessment. The g…

This study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…

This study aims to find new biological markers (biomarkers) that can show how active acute porphyria is in the body and how well treatments are working. Researchers will study 50 people with confirmed acute porphyria to measure gene activity related to heme production and stress …

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…

This study was designed to collect information on pregnancy and baby outcomes in women who received the PREHEVBRIO hepatitis B vaccine around the time of conception or during pregnancy. The goal was to watch for any safety concerns, such as miscarriage or birth defects. However, …

This study surveys 30 adults with Wilson disease to learn about their daily management, treatment adherence, and interest in gene editing clinical trials. By gathering this information, researchers hope to design better future studies for potential gene therapies targeting specif…

This study looks at how amino acids trigger the liver to release hormones in healthy people and those with non-alcoholic fatty liver disease. Researchers will give amino acid infusions with or without a drug that blocks natural hormone production. By comparing the results, they h…

This study tests a new wireless sensor that continuously measures the light dose babies receive during phototherapy for jaundice. Currently, doctors check light levels only once a day with a handheld device, which can be inaccurate. The sensor aims to provide real-time data to en…

This study measures levels of a substance called 4beta-hydroxycholesterol in the blood of people with liver cirrhosis. It compares these levels to those in people with pneumonia, Crohn's disease, or ulcerative colitis. The goal is to understand how cirrhosis and certain medicatio…

This study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…

This study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.

This study is testing a new type of clinic that screens people with prediabetes and type 2 diabetes for several hidden health problems at the same time, including fatty liver disease, sleep apnea, and heart failure. The goal is to see how common these undiagnosed conditions are a…

This study looks at 240 adults with liver cirrhosis to learn more about a common complication called portal vein thrombosis (a blood clot in the liver's main vein). Researchers will use ultrasound and CT scans to find clots and track their patterns. The goal is to identify which …

This study looks at whether simple blood tests and special scans can detect liver scarring in people with urea cycle disorders. Researchers will enroll 62 participants across five U.S. centers. The goal is to find noninvasive ways to monitor liver health, avoiding the need for li…

This study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…

This study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …

This study tests a new, longer MRI scan that measures liver stiffness and viscosity to see if it can identify NASH patients at higher risk for liver cancer. About 35 adults with NASH and early-stage liver scarring will participate. The goal is to improve early detection, not to t…

This study gathers blood, urine, stool, and tissue samples from 132 adults with primary liver cancer who are receiving or have received immunotherapy. Researchers will analyze these samples along with medical records to learn more about how liver cancer develops and responds to t…

This study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…

This study is a registry that will review medical records of 1,000 patients treated for benign or malignant gastrointestinal diseases between 2005 and 2030. Researchers will look at survival, symptoms like heartburn and swallowing trouble, and quality of life. The goal is to lear…

This study looks at 2000 patients with acute-on-chronic liver failure caused by hepatitis B. Researchers will collect blood samples and medical data to build a model that predicts survival and complications at different time points. The goal is to give doctors a better way to est…

This study follows 10,000 adults with hepatocellular carcinoma (a type of liver cancer) to see how the disease changes over time and how different treatments affect patients in real life. Researchers are collecting information from regular doctor visits and patient surveys, and b…

This study is screening 1,000 patients at the HOPE clinic in Houston for liver fibrosis and cirrhosis using surveys, blood tests, and a non-invasive liver scan called FibroScan. The goal is to find early signs of liver damage that could lead to cancer, so that prevention or early…

This study aims to create a questionnaire that measures how patients feel about their experience during endoscopic ultrasound, a procedure used to examine the pancreas and bile ducts. Researchers will ask 171 outpatients at a hospital in Italy to rate their experience, and compar…

This study planned to test a growth factor medicine (Increlex) in children aged 4-18 with chronic liver disease and short stature. The goal was to see if it could improve growth and quality of life. However, the study was withdrawn before any participants were enrolled, so no res…

This study follows 50 children with single-ventricle heart disease who have had the Fontan operation. Researchers use a special ultrasound to measure liver stiffness, which may indicate congestion and predict future complications like liver disease. The goal is to find a noninvas…

This study follows 100,000 Chinese families from before pregnancy through the child's teenage years. Researchers collect health data, biospecimens, and environmental information to understand how parents' exposures affect pregnancy outcomes and child development. The goal is to f…

This study looks at whether offering dental exams and cleanings to people with cirrhosis can improve their oral health and overall well-being. Researchers will also ask participants about barriers to getting dental care. About 100 adults with confirmed cirrhosis will take part, a…

This pilot study was designed to see if a special MRI technique called field-cycling imaging could tell the difference between simple fatty liver and more serious liver scarring (fibrosis) in adults with non-alcoholic fatty liver disease (NAFLD). The goal was to find a non-invasi…

This study follows 500 obese adults to see how different factors like diet, exercise, stress, and sleep affect weight loss. Researchers collect blood tests, measurements, and questionnaires at the start and during follow-up. The goal is to find patterns that could lead to more pe…

This study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and …

This study was designed to measure estrogen and testosterone levels in men with liver cirrhosis who also have low blood pressure, compared to those with cirrhosis but normal blood pressure. The goal was to understand why low blood pressure occurs in cirrhosis. However, the study …

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This phase 2 trial tests whether a software-aided imaging system (Morfeus) can help doctors confirm that liver tumors are fully covered during ablation. About 107 patients with up to 3 liver tumors will be treated with standard ablation, and the software will be used to assess th…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study compares two catheters used during the mapping step before radioembolization for liver cancer. One is a standard microcatheter, the other is a pressure-enabled device (TriNav). The goal is to see if the pressure-enabled catheter delivers more radioactive tracer directl…

This study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare resu…

This study is testing a new blood test to see if it can find tiny bits of bile duct cancer left behind after treatment. Researchers will follow 100 adults who are having surgery to remove their cancer. The goal is to see if the test can predict if the cancer will come back sooner…

This study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…

This study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …

This study looks at why people with severe liver disease who are in the intensive care unit (ICU) are at risk for a dangerous fungal lung infection called invasive pulmonary aspergillosis. Researchers will study 450 patients to find better ways to predict, diagnose, and treat thi…

This observational study will follow up to 500,000 adults with chronic liver disease or cirrhosis to understand how the disease progresses and how treatments are used in everyday practice. Researchers will collect data from medical records and patient reports to improve care and …

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study compares two non-invasive methods for monitoring brain blood flow during liver transplant surgery: carotid Doppler ultrasound and near-infrared spectroscopy (NIRS). The goal is to see if the simpler, cheaper ultrasound can replace the more expensive NIRS. The study inv…

This study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…

This study tests whether an automatic reminder in the electronic health record can increase the number of cirrhosis patients who get screened for liver cancer (hepatocellular carcinoma). The reminder prompts doctors to order a liver ultrasound when they see a patient with cirrhos…

This study explores whether 3D bioprinting can create personalized models of liver cancer from a patient's own tumor tissue. Researchers will test different drugs on these models to see which ones work best, aiming to predict a patient's response before treatment. The goal is to …

This study looks back at medical records of 624 adults with liver cirrhosis who had a procedure called TIPS to relieve pressure in the liver. The goal is to create a simple tool that helps doctors predict which patients are at high risk for a brain complication called hepatic enc…

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…

This study looks at babies born to mothers with intrahepatic cholestasis of pregnancy (ICP), a liver condition that causes itching and high bile acid levels. Researchers want to see if these bile acids can lead to breathing problems in newborns. They will compare 120 babies—some …

This study uses interviews and questionnaires to learn how primary care doctors and Hispanic patients think about non-alcoholic fatty liver disease (NAFLD). Researchers want to understand what doctors know about diagnosing and treating NAFLD, and how cultural factors affect patie…